[작성자:] cms3billion
-
3billion’s 5-Week Turnaround Time for Genetic Insights
One of the biggest challenges physicians face when diagnosing rare diseases is the time it takes to receive Whole Genome Sequencing (WGS) or Whole Exome Sequencing (WES) results. Traditionally, healthcare providers have faced TATs spanning several weeks to months, delaying essential diagnostic decisions and impacting patient care Recognizing this pain point, we at 3billion have…
-
쓰리빌리언, 유전자 데이터 보안을 위한 ISO/IEC 27001:2022 인증 획득
3billion은 최근 정보 보안 관리 시스템(ISMS)에 대한 국제적으로 인정받은 표준인 ISO/IEC 27001:2022 인증을 획득했습니다. 본 인증을 받음으로써 쓰리빌리언은 민감한 환자의 유전자 데이터를 보호하고, 유전자 검사 과정과 소프트웨어 솔루션에서 최고 수준의 보안 기준을 유지하려는 강력한 의지를 다졌습니다. 이 인증이 중요한 이유 오늘날의 디지털 시대에서는 정보 보안이 그 어느 때보다 중요해졌습니다. 헬스케어와 유전자 검사가 클라우드 기반 플랫폼을…
-
Microarray vs Whole-Exome Sequencing (WES): Which Genetic Test is Right for Rare Disease Diagnosis?
In this article, we explore the key differences between Microarray and WES, highlighting their respective roles in diagnosing rare diseases and how they can complement each other for more comprehensive evaluations. Chromosomal Microarray Test Chromosomal Microarray Analysis (CMA) is a high-resolution genetic test used to detect copy number variations (CNVs), such as deletions or duplications,…
-
3billion Secures ISO/IEC 27001:2022 Certification for Information Security Management in Genetic Testing
At 3billion, we are proud to announce that we have achieved ISO/IEC 27001:2022 certification, an internationally recognized standard for information security management systems (ISMS). This certification solidifies our commitment to safeguarding sensitive patient genetic data and maintaining the highest security standards in our genetic testing processes and software solutions. Why This Certification Matters In today’s…